뒤로
Reviva Pharmaceuticals Holdings Inc (RVPH) 수입
RVPH 주가 차트
RVPH 수입
Reviva Pharmaceuticals Holdings Inc
$0.64
-12.37%
$-0.09
오늘 기준:Mar 30, 12:31:38 GMT-4
최신 수익 결과: Q3 '25
보고됨: 2025-11-13
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
RVPH의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Reviva Pharmaceuticals Holdings Inc RVPH의 지난 분기 매출 실적은 어땠나요?
Reviva Pharmaceuticals Holdings Inc의 매출 추정치는 얼마인가요?
Reviva Pharmaceuticals Holdings Inc의 수익 품질 점수는 얼마인가요?
Reviva Pharmaceuticals Holdings Inc는 언제 수익을 보고하나요?
Reviva Pharmaceuticals Holdings Inc의 예상 수익은 얼마인가요?
Reviva Pharmaceuticals Holdings Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.7416
시가
$0.7547
일일 범위
$0.59 - $0.79
52주 범위
$0.6498 - $23.4
거래량
591.5K
평균 거래량
413.6K
배당수익률
--
EPS(TTM)
-0.47
시가총액
$4.1M
RVPH란 무엇인가요?
Reviva Pharmaceuticals Holdings Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Cupertino, California and currently employs 14 full-time employees. The company went IPO on 2018-10-18. Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The firm discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).